Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2011

Open Access 01-12-2011 | Study protocol

Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study

Authors: Gelsomina L Borromeo, Caroline Brand, John G Clement, Michael McCullough, Wendy Thomson, Elly Flitzanis, John D Wark

Published in: BMC Musculoskeletal Disorders | Issue 1/2011

Login to get access

Abstract

Background

Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 year's duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing.

Methods/Design

A case-control study has been chosen to test the hypothesis as the outcome event rate is likely to be very low. A total of 54 cases will be recruited into the study following review of all dental files from oral and maxillofacial surgeons and special needs dentists in Victoria where potential cases of delayed dental healing will be identified. Potential cases will be presented to an independent case adjudication panel to determine if they are definitive delayed dental healing cases. Two hundred and fifteen controls (1:4 cases:controls), matched for age and visit window period, will be selected from those who have attended local community based referring dental practices. The primary outcome will be the incidence of delayed dental healing that occurs either spontaneously or following dental treatment such as extractions, implant placement, or denture use.

Discussion

This study is the largest case-controlled study assessing the link between bisphosphonate use and delayed dental healing in Australia. It will provide invaluable data on the potential link between bisphosphonate use and osteonecrosis of the jaws.
Appendix
Available only for authorised users
Literature
1.
2.
Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000, 18 (6): 1378-1391.PubMed
3.
Durie BG: Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007, 82 (4): 516-517. 10.4065/82.4.516. author reply 517-518CrossRefPubMed
4.
Berenson JR: Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol. 2001, 28 (2 Suppl 6): 25-34. 10.1016/S0093-7754(01)90262-3.CrossRefPubMed
5.
Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R: Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009, 24 (9): 1544-1551. 10.1359/jbmr.090310.CrossRefPubMed
6.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356 (18): 1809-1822. 10.1056/NEJMoa067312.CrossRefPubMed
7.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009, 373 (9671): 1253-1263. 10.1016/S0140-6736(09)60250-6.CrossRefPubMed
8.
Sambrook P, Cooper C: Osteoporosis. Lancet. 2006, 367 (9527): 2010-2018. 10.1016/S0140-6736(06)68891-0.CrossRefPubMed
9.
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008, CD001155-1
10.
Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD: Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev. 2003, CD004523-4
11.
Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008, CD004523-1
12.
Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE: Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995, 10 (6): 956-962. 10.1002/jbmr.5650100617.CrossRefPubMed
13.
Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006, 2 (4): 211-219. 10.1038/ncpendmet0121. quiz following 238CrossRefPubMed
14.
Pazianas M, Cooper C, Ebetino FH, Russell RG: Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 6: 325-343.
15.
Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R: Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab. 2009, 27 (4): 435-443. 10.1007/s00774-009-0047-9.CrossRefPubMed
16.
Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M: Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009, 112 (3): 605-609. 10.1016/j.ygyno.2008.11.029.CrossRefPubMed
17.
Carter G, Goss AN, Doecke C: Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005, 182 (8): 413-415.PubMed
18.
Purcell PM, Boyd IW: Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005, 182 (8): 417-418.PubMed
19.
Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005, 34 (2): 120-123. 10.1111/j.1600-0714.2004.00269.x.CrossRefPubMed
20.
Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003, 61 (9): 1115-1117. 10.1016/S0278-2391(03)00720-1.CrossRefPubMed
21.
Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD: Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009, 27 (2): 221-226. 10.1080/07357900802208608.CrossRefPubMedPubMedCentral
22.
Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 68 (2): 243-253. 10.1016/j.joms.2009.03.050.
23.
Hellstein JW, Marek CL: Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005, 63 (5): 682-689. 10.1016/j.joms.2005.01.010.CrossRefPubMed
24.
Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ: Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007, 65 (7): 1328-1331. 10.1016/j.joms.2007.03.006.CrossRefPubMed
25.
Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005, 353 (1): 99-102. 10.1056/NEJM200507073530120. discussion 199-102CrossRefPubMed
26.
Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008, 23 (6): 826-836. 10.1359/jbmr.080205.CrossRefPubMed
27.
Migliorati CA: Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005, 99 (2): 135-10.1016/j.tripleo.2004.10.001.CrossRefPubMed
28.
Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS: Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007, 99 (13): 1016-1024. 10.1093/jnci/djm025.CrossRefPubMed
29.
Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006, 2 (1): 7-14. 10.1200/JOP.2.1.7.CrossRefPubMedPubMedCentral
30.
31.
Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008, 26 (24): 4037-4038. 10.1200/JCO.2007.15.5424.CrossRefPubMed
32.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28 (35): 5132-5139. 10.1200/JCO.2010.29.7101.
33.
Hansen T, Kirkpatrick CJ, Walter C, Kunkel M: Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis--a paradoxical observation?. Virchows Arch. 2006, 449 (4): 448-454. 10.1007/s00428-006-0261-y.CrossRefPubMed
34.
Greenberg MS: Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004, 98 (3): 259-260. 10.1016/j.tripleo.2004.08.001.CrossRefPubMed
35.
Ruggiero SL, Mehrotra B: Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009, 60: 85-96. 10.1146/annurev.med.60.063007.134350.CrossRefPubMed
36.
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G: The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 141 (11): 1365-1370.
37.
Jung TI, Hoffmann F, Glaeske G, Felsenberg D: Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol. 136 (3): 363-370. 10.1007/s00432-009-0662-9.
38.
Slade GSA, Roberts-Thompson K: Australia's dental generations: the National Surveyof Adult oral 2004-6. Canberra: Australian Institute of Health and Welfare (Dental Statistics and Research Series No 34). 2007
39.
Statistics ABo: National Health Survey: Summary of results, Australia. 2004
40.
Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007, 65 (3): 415-423. 10.1016/j.joms.2006.10.061.CrossRefPubMed
41.
Takagi Y, Sumi Y, Harada A: Osteonecrosis associated with short-term oral administration of bisphosphonate. J Prosthet Dent. 2009, 101 (5): 289-292. 10.1016/S0022-3913(09)00049-3.CrossRefPubMed
42.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007, 22 (10): 1479-1491. 10.1359/jbmr.0707onj.CrossRefPubMed
43.
Vinckier F, Vermylen J: Wound healing following dental extractions in rabbits: effects of tranexamic acid, warfarin anti-coagulation, and socket packing. J Dent Res. 1984, 63 (5): 646-649. 10.1177/00220345840630050701.CrossRefPubMed
44.
Bagan J, Blade J, Cozar JM, Constela M, Garcia Sanz R, Gomez Veiga F, Lahuerta JJ, Lluch A, Massuti B, Morote J: Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007, 12 (4): E336-340.PubMed
45.
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007, 65 (3): 369-376. 10.1016/j.joms.2006.11.003.
46.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009, 67 (5 Suppl): 2-12.PubMed
47.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009, 35 (3): 119-130. 10.1111/j.1747-4477.2009.00213.x.CrossRefPubMed
48.
Ruggiero SL, Fantasia J, Carlson E: Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006, 102 (4): 433-441. 10.1016/j.tripleo.2006.06.004.CrossRefPubMed
49.
Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME: Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002, 32 (2): 94-124.CrossRefPubMed
50.
Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, Kwan I: Increasing response rates to postal questionnaires: systematic review. Bmj. 2002, 324 (7347): 1183-10.1136/bmj.324.7347.1183.CrossRefPubMedPubMedCentral
Metadata
Title
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study
Authors
Gelsomina L Borromeo
Caroline Brand
John G Clement
Michael McCullough
Wendy Thomson
Elly Flitzanis
John D Wark
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2011
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-12-71

Other articles of this Issue 1/2011

BMC Musculoskeletal Disorders 1/2011 Go to the issue

Correspondence

Comparison of published orthopaedic trauma trials following registration in Clinicaltrials.gov

Study protocol

Comparison of standard fusion with a "topping off" system in lumbar spine surgery: a protocol for a randomized controlled trial

Study protocol

Self management, joint protection and exercises in hand osteoarthritis: a randomised controlled trial with cost effectiveness analyses

Research article

A prospective study of shoulder pain in primary care: Prevalence of imaged pathology and response to guided diagnostic blocks

Research article

Trends in primary total hip arthroplasty in Spain from 2001 to 2008: Evaluating changes in demographics, comorbidity, incidence rates, length of stay, costs and mortality

Study protocol

Comparison of neuromuscular and quadriceps strengthening exercise in the treatment of varus malaligned knees with medial knee osteoarthritis: a randomised controlled trial protocol